Irkutsk, Irkutsk region, Russian Federation
Irkutsk, Irkutsk region, Russian Federation
Irkutsk, Irkutsk region, Russian Federation
Cel' raboty: izuchit' soderzhanie markerov kostnogo metabolizma u zhenschin s saharnym diabetom (SD) 2-go tipa v postmenopauzal'nom periode. Obsledovano 28 zhenschin, iz nih 15 – s SD 2 tipa i 13 – kontrol'noy gruppy. Opredelyalis' urovni ionizirovannogo kal'ciya, 25-OH vitamina D, osteokal'cina, N-terminal'nogo propeptida prokollagena 1-go tipa, S-koncevyh telopeptidov kollagena I tipa. Predstavlena ocenka potrebleniya kal'ciya. Pokazano suschestvennoe snizhenie markerov osteosinteza i osteorezorbcii u bol'nyh SD 2 tipa otnositel'no pokazateley kontrol'noy gruppy.
saharnyy diabet, osteoporoz, nedostatochnost'/deficit vitamina D, FRAX
1. Kolesnikova LI, Bardymova TP, Petrova VA, Dolgikh MI, Darenskaya MA, Grebyonkina LA, Natyaganova LV. (2006). Ethnic aspects in lipid and carbohydrate metabolism in patients with diabetes mellitus type 1 [Etnicheskie osobennosti lipidnogo i uglevodnogo obmenov u bol’nykh sakharnym diabetom 1 tipa]. Bulleten’ Vostocno-Sibirskogo naucnogo centra, (1), 127-130.
2. Lesnyak OM. (2011). Audit of osteoporosis problem in Eastern Europe and Central Asia in 2010 [Audit sostoyaniya problemy osteoporoza v stranakh vostochnoy Evropy i Tsentral’noy Azii 2010]. Osteoporoz i osteopatii, (2), 3-6.
3. Mokrysheva NG, Rozhinskaya LY. (2013). Modern view on the effectiveness of postmenopausal osteoporosis therapy. Innovative targeted therapy drugs [Sovremennyy vzglyad na effektivnost’ terapii postmenopauzal’nogo osteoporoza. Innovatsionnye preparaty targetnoy terapii]. Osteoporoz i osteopatii, (1), 29-33.
4. Rozhinskaya LY. (2012). Modern strategies for prevention and treatment of postmenopausal osteoporosis [Sovremennye strategii profilaktiki i lecheniya postmenopauzal’nogo osteoporoza]. Meditsinskiy sovet, (7), 20-23.
5. Barrera G, Bunout D, Gattás V, de la Maza MP, Leiva L, Hirsch S. (2004). A high body mass index protects against femoral neck osteoporosis in healthy elderly subjects. Nutrition, 20 (9), 769-771.
6. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY. (2005). Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis Int., 16 (3), 1657-1680.
7. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL (1996). Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcified Tissue Int., 59 (5), 328-333.
8. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. (1999). Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY Study. J. Bone Miner. Res., 14 (9), 1614-1621.
9. Hansen MA, Overgaard K, Riis BJ, Christiansen C. (1991). Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12-year study. BMJ, (303), 961-964.
10. IDF. Diabetes atlas. Available at: http://www.idf.org/sites/default/files/attachments/Atlas-poster-RU.pdf (date of access 01.10.2016).
11. Rosen CJ, Bouxsein ML. (2006). Mechanisms of disease: is osteoporosis the obesity of bone? Nat. Clin. Pract. Rheumatol., 2 (1), 35-43.
12. Ross P, Knowlton W. (1998). Rapid bone loss is associated with increased levels of biochemical markers. J. Bone Miner. Res., 13 (2), 297-302.
13. Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE. (2006). Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporosis Int., 18 (2), 201-210.
14. Vestergaard P. (2007). Discrepancies in bone mineral density and fracture risk in patients with type 1 and type2 diabetes - a meta-analysis. Osteoporos Int., 18 (4), 427-444.
15. Yoshizawa T. (2016). Osteocalcin and osteonetwork. Clin. Calcium, 26 (8), 1149-1156.
